标题
Etelcalcetide for the treatment of secondary hyperparathyroidism
作者
关键词
-
出版物
EXPERT OPINION ON PHARMACOTHERAPY
Volume 18, Issue 5, Pages 529-534
出版商
Informa UK Limited
发表日期
2017-03-04
DOI
10.1080/14656566.2017.1303482
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism
- (2017) Geoffrey A. Block et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism
- (2017) Geoffrey A. Block et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
- (2016) Tadao Akizawa et al. Scientific Reports
- Treatment of Secondary Hyperparathyroidism: Results of a Phase 2 Trial Evaluating an Intravenous Peptide Agonist of the Calcium-Sensing Receptor
- (2015) David A. Bushinsky et al. AMERICAN JOURNAL OF NEPHROLOGY
- A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients
- (2015) Gregory Bell et al. CURRENT MEDICAL RESEARCH AND OPINION
- Population pharmacokinetics analysis of AMG 416, an allosteric activator of the calcium-sensing receptor, in subjects with secondary hyperparathyroidism receiving hemodialysis
- (2015) Ping Chen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism
- (2015) Geert J. Behets et al. KIDNEY INTERNATIONAL
- Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: the EVOLVE trial
- (2015) Yumi Kubo et al. PHARMACEUTICAL STATISTICS
- Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial
- (2014) S. M. Moe et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients
- (2013) Kevin J. Martin et al. KIDNEY INTERNATIONAL
- Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects
- (2013) K. J. Martin et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Effect of cinacalcet availability and formulary listing on parathyroidectomy rate trends
- (2013) Jean-Philippe Lafrance et al. BMC Nephrology
- Cinacalcet in Patients with Chronic Kidney Disease: A Cumulative Meta-Analysis of Randomized Controlled Trials
- (2013) Suetonia C. Palmer et al. PLOS MEDICINE
- Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Parathyroidectomy Rates in US Hemodialysis Patients From 1992 to 2007
- (2010) Suying Li et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Cinacalcet Effectively Reduces Parathyroid Hormone Secretion and Gland Volume Regardless of Pretreatment Gland Size in Patients with Secondary Hyperparathyroidism
- (2010) H. Komaba et al. Clinical Journal of the American Society of Nephrology
- The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis
- (2010) P. Raggi et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search